Alexander Haumer

Dr. Alexander Haumer


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
AHAlexander Haumer
Alexander Haumer
PBPaul Emile Bourgine
Paul Emile Bourgine
Paola OcchettaPaola Occhetta
Paola Occhetta
GBGordian Born
Gordian Born
Roberta TassoRoberta Tasso
Roberta Tasso
IMIvan Martin
Ivan Martin

1 November 2017 in Acta Biomaterialia
Verified
Journal Article
Closed access
TITarek Ismail
Tarek Ismail
RORik Osinga
Rik Osinga
ATAtanas Todorov
Atanas Todorov
AHAlexander Haumer
Alexander Haumer
LTLaurent A. Tchang
Laurent A. Tchang
ASArnaud Scherberich
Arnaud Scherberich

16 June 2017
Verified
Book Chapter
Closed access
PDF file
AHAlexander Haumer
Alexander Haumer
TITarek Ismail
Tarek Ismail
ALAlexander Lunger
Alexander Lunger
RORik Osinga
Rik Osinga
ASArnaud Scherberich
Arnaud Scherberich
IMIvan Martin
Ivan Martin

1 June 2018 in Plastic and Reconstructive Surgery - Global Open
Verified
Journal Article
Open access
TITarek Ismail
Tarek Ismail
RORik Osinga
Rik Osinga
ATAtanas Jr. Todorov
Atanas Jr. Todorov
AHAlexander Haumer
Alexander Haumer
LTLaurent A. Tchang
Laurent A. Tchang
SWSwitzerland
Switzerland

Verified
Journal Article
Open access
PDF file
PPPablo Pfister
Pablo Pfister
GZGangyu Zhang
Gangyu Zhang
SPSébastien Pigeot
Sébastien Pigeot
AMAdrien Moya
Adrien Moya
AHAlexander Haumer
Alexander Haumer
ASArnaud Scherberich
Arnaud Scherberich
Reconstruction of large craniofacial bone defects typically relies on vascularized autografts, but involves donor-site morbidity and limited availability. Tissue-engineered vascularized grafts could address this gap; however, current strategies remain limited by in vitro cell manipulation, regulatory complexity, high costs, and difficult clinical scaling up. We previously prefabricated a maxillary graft combining a devitalized bone matrix (DBM), freshly isolated human adipose-derived cells, known as the stromal vascular fraction (SVF), and Bone Morphogenetic protein-2 (BMP-2). Here, we tested if cells were essential by developing a cell-free approach with only DBM (SmartBone) and BMP-2. SmartBone blocks were loaded with BMP-2 (60 µg/mL in a fibrin hydrogel) with or without SVF cells and implanted subcutaneously in nude mice for 12 weeks (ectopic model) or combined to an axial arteriovenous (AV) bundle in nude rats (785 mm3) for 2 or 12 weeks (vascularized model). Bone formation was assessed by X-ray tomography and histology. Across both mice and rats, BMP-2 alone was sufficient to generate robust and organized bone, and adding SVF cells provided no additional benefit at this BMP-2 dosage. In mice, BMP-2 grafts formed lamellar bone with marrow, while grafts without BMP-2 produced only calcified fibrous tissue. Bone and marrow volumes did not differ between BMP-2 and BMP-2 + SVF groups (p > 0.05). In rats, both conditions showed significant increases in mineralized volume from 2 to 12 weeks (p < 0.05). In conclusion, the dose of BMP-2 tested here, combined with DBM, is enough to robustly generate pedicled bone grafts while using off-the-shelf, approved materials and microsurgical prefabrication, providing a simplified, translationally feasible approach for the reconstruction of large bone defects.

9 June 2021
Verified
Book Chapter
Closed access
PDF file
AHAlexander Haumer
Alexander Haumer
TITarek Ismail
Tarek Ismail
ALAlexander Lunger
Alexander Lunger
RORik Osinga
Rik Osinga
ASArnaud Scherberich
Arnaud Scherberich
IMIvan Martin
Ivan Martin